Articles By Rob Wright, Chief Editor 2011-2021
It’s Time We Ready Americans For The COVID-19 Long Haul7/15/2020
Rob Wright issues a call to action to everyone connected to the biopharmaceutical industry, recommending they begin communicating the realities of developing and distributing a COVID-19 vaccine by the end of this year.
A Small Biopharma’s View Of Working With CROs7/1/2020
Running a clinical-stage oncology biopharma with only five employees means you quickly learn a thing or two about the value of outsourcing services. For Pamela Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics, those learnings have led to her company using five CROs for the company’s lead investigational candidate.
Aligos Therapeutics — The Next Step Of Lawrence Blatt’s Entrepreneurial Expedition7/1/2020
Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, discusses the entrepreneurial journey that took him from startup, to Big Pharma, back to startup.
Building A Digital Therapeutics Company7/1/2020
Brent Vaughan talks about the differences between building a biotech and building a digital therapeutics company.
What’s With All The Stuff On Corporate Culture?7/1/2020
If you found a moment of tranquility during the lockdown of this pandemic, then you may have started to reflect on what’s really important — at home and the office. I recently found myself pondering the concept of corporate culture.
Readying For A Virtual Fireside Chat With A Biomanufacturing Icon6/25/2020
Biomanufacturing icon Andy Skibo, and Life Science Leader chief editor Rob Wright, on topics and planning for upcoming fireside chat at the American Biomanufacturing Summit 2020 that has now gone virtual.
BIO Digital Makes The Best Of A Bad COVID-19 Situation6/15/2020
Life Science Leader’s Rob Wright provides perspective on BIO Digital 2020, and a recommendation for the session every BIO Digital registered attendee should make time to attend.
A Chat On Biosimilars With Sandoz’s U.S. President Carol Lynch6/1/2020
Carol Lynch, president of Sandoz U.S. and head of North America, fields biosimilars-related questions from the audience at the 2020 BIO CEO & Investor Conference.
How One Professor Built Two Billion-Dollar Biotechs6/1/2020
Professor Ugur Sahin, M.D., Ph.D. never wanted to be an entrepreneur. Yet, today he’s the cofounder and CEO of BioNTech, a publicly traded German biotech aspiring to develop individualized cancer medicines. It was a surprising career path switch.